Recent Updates — ISCO

International Stem Cell Corporation completed the sale of 100% of its wholly-owned subsidiary, Lifeline Cell Technology, LLC (LCT), to American Type Culture Collection, Inc. on September 1, 2026. The transaction carries an adjusted purchase price of $25,250,000, comprising a base price of $25,000,000 and a fixed cash add-back of $250,000, subject to post-closing working capital adjustments. Net cash proceeds received at closing totaled approximately $21,688,000 after deducting transaction costs and escrow withholdings. The company recognized an estimated pre-tax gain on sale of $22,174,000, resulting in an after-tax gain credited to accumulated deficit of approximately $19,316,000 excluding the escrow holdback. LCT’s historical financial results will be classified as discontinued operations moving forward. International Stem Cell Corporation operates in the biotechnology and life sciences industry, focusing on therapeutic research and development.

On July 10, 2026, International Stem Cell Corporation entered into a Membership Interest Purchase Agreement to sell 100% of Lifeline Cell Technology, LLC (LCT) to American Type Culture Collection, Inc. for an aggregate purchase price of $25.0 million, subject to adjustments for net working capital, cash, and indebtedness. The transaction includes a $100,000 adjustment escrow and a $2.5 million indemnity escrow. Requisite holders representing over 50% of Seller's voting power have entered into support agreements to vote in favor of the transaction. Closing is expected in the third fiscal quarter of 2026. International Stem Cell Corporation is a biotechnology company involved in stem cell research and development.